Global Blood Therapeutics (GBT) PT Raised to $110 at Cantor Fitzgerald Amid HOPE Trial Results
Tweet Send to a Friend
Cantor Fitzgerald analyst Elemer Piros raised the price target on Global Blood Therapeutics (NASDAQ: GBT) to $110.00 (from $96.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
